Chris Schott is ranked #959 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

JPM

Chris Schott

Q: How accurate are Chris Schott's stock ratings?

About 67% of Chris's ratings were profitable over a one-year hold, with an average return of +3.9% per rating, measured by 13Foresight from historical prices.

J.P. Morgan

Wall Street Analyst

★★★☆☆

#959

on 13Foresight · ranked by our own returns

67%

Success Rate

+3.9%

Average Return

35 of 52 calls profitable · -2.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 67% of Chris Schott's ratings turned a profit when each position was held for 1 year — averaging +3.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

81 Buy 39 Hold 3 Sell

Chris's Stock Coverage 27 ratings · 2026-08-12

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
ZTS Zoetis	Aug 10, 2026	BUY	Buy +59.1% avg upside 23 analysts	$115.00 52.59% Upside	-1.7%	·
VTRS Viatris	Aug 10, 2026	HOLD	Buy +44.1% avg upside 21 analysts	$18.00 10.66% Upside	·	·
RPRX Royalty Pharma	Aug 10, 2026	BUY	Strong Buy +0.5% avg upside 15 analysts	$62.00 7.34% Upside	+2.2%	·
GILD Gilead Sciences	Aug 06, 2026	BUY	Strong Buy -12.1% avg upside 66 analysts	$160.00 17.80% Upside	+1.7%	·
AMGN Amgen	Aug 06, 2026	HOLD	Buy -23.9% avg upside 57 analysts	$350.00 15.62% Downside	+3.0%	·
LLY Eli Lilly & Co	Aug 06, 2026	BUY	Strong Buy -13.8% avg upside 48 analysts	$1400.00 15.20% Upside	+2.4%	·
ELAN Elanco Animal Health	Aug 06, 2026	BUY	Strong Buy +38.0% avg upside 18 analysts	$33.00 45.09% Upside	-8.6%	·
MRK Merck & Company	Aug 06, 2026	BUY	Strong Buy -0.7% avg upside 43 analysts	$150.00 15.00% Upside	+1.6%	·
PFE Pfizer	Aug 04, 2026	HOLD	Buy +25.8% avg upside 45 analysts	$28.00 5.18% Upside	+6.5%	·
REGN Regeneron	Aug 04, 2026	BUY	Strong Buy -2.1% avg upside 58 analysts	$900.00 12.90% Upside	+3.1%	·
BMY Bristol-Myers Squibb	Aug 04, 2026	BUY	Buy -4.4% avg upside 42 analysts	$73.00 14.79% Upside	-1.6%	·
BIIB Biogen	Jul 30, 2026	HOLD	Strong Buy +23.5% avg upside 52 analysts	$210.00 2.96% Upside	+0.0%	·
JNJ Johnson & Johnson	Jul 16, 2026	HOLD	Strong Buy -9.2% avg upside 39 analysts	$270.00 4.02% Upside	+3.9%	·
ABBV AbbVie	Jul 09, 2026	BUY	Strong Buy -4.3% avg upside 46 analysts	$280.00 11.87% Upside	+0.2%	·
TEVA Teva Pharmaceutical	Jun 15, 2026	BUY	Buy -17.3% avg upside 39 analysts	—	+5.1%	·
AMRX Amneal Pharmaceuticals	Mar 02, 2026	BUY	Strong Buy +3.6% avg upside 18 analysts	$18.00 5.29% Upside	+24.2%	·
PRGO Perrigo Company	Feb 27, 2026	HOLD	Buy +431.9% avg upside 20 analysts	$15.00 16.77% Upside	+1.9%	·
OGN Organon	Feb 13, 2026	SELL	Sell +8.9% avg upside 9 analysts	$11.00 19.51% Downside	-85.6%	·
IDXX Idexx Laboratories	Nov 03, 2025	BUY	Buy +22.8% avg upside 17 analysts	$775.00 32.09% Upside	-21.1%	·
CHRS Coherus Biosciences	May 25, 2023	HOLD	Buy +923.6% avg upside 18 analysts	$8.00 561.21% Upside	-55.5%	·
TSE:BHC Bausch Health Companies	Jul 28, 2022	HOLD	Buy +568.6% avg upside 29 analysts	—	+130.2%	·
TXMD TherapeuticsMD	May 19, 2020	HOLD	Buy +201.9% avg upside 8 analysts	—	·	·
DE:MRK Merck KGaA	Mar 09, 2020	BUY	Buy -2.2% avg upside 33 analysts	$84.77 39.53% Downside	+34.2%	·
PCRX Pacira Pharmaceuticals	Feb 20, 2020	HOLD	Buy +60.2% avg upside 21 analysts	$54.00 121.41% Upside	+51.7%	·
SNNAQ Sienna Biopharmaceuticals	May 13, 2019	HOLD	Buy +299999900.0% avg upside 2 analysts	—	·	·
KALA KALA BIO	Nov 17, 2017	BUY	Strong Buy +27915.7% avg upside 9 analysts	$35.00 4042.42% Upside	·	·
AMRN Amarin	Oct 17, 2013	HOLD	Buy -39.8% avg upside 18 analysts	—	-47.8%	·

🔒 22 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Chris Schott — Frequently Asked Questions

How accurate are Chris Schott's stock ratings?

Based on the calls 13Foresight could measure, about 67% of Chris's ratings were profitable over a one-year hold, with an average return of +3.9% per rating, or -2.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Chris ranked on 13Foresight?

Chris Schott is currently ranked #959 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Chris cover?

Chris most recently has ratings on ZTS, VTRS, RPRX, GILD, AMGN, LLY, ELAN, MRK, PFE, REGN, BMY, BIIB and 15 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Chris Schott

Rating Distribution

Welcome to 13Foresight!